Cymabay Therapeutics Inc
CBAY
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.73B
Close$
$4.85
85.1% downside
Current Fair Value
85.1% downsideOvervalued by 85.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.73 Billion |
|---|---|
| Enterprise Value | $3.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.99 |
| Beta | 0.32 |
| Outstanding Shares | 113,323,386 |
Return
| Return on Equity | -38.21% |
|---|---|
| Return on Assets | -25.69% |
| Return on Invested Capital | -24.63% |
Valuation & Multiples
| P/E Ratio | -32.74 |
|---|---|
| PEG | -215.72 |
| Price to Sales | - |
| Price to Book Ratio | 16.24 |
| Enterprise Value to Revenue | 116.9 |
| Enterprise Value to EBIT | -37.07 |
| Enterprise Value to Net Income | -33 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.38 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cymabay Therapeutics Inc
CEO: Sujal Shah